Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 50 Triple Negative Breast Neoplasms 41 Carcinoma, Non-Small-Cell Lung 11 Head and Neck Neoplasms 8 Carcinoma, Renal Cell 8 Ovarian Neoplasms 7 Melanoma 6 Carcinoma, Hepatocellular 6 Pancreatic Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 5 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Prostatic Neoplasms 3 Gastrointestinal Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Merkel Cell 3 Urogenital Neoplasms 2 Lymphoma 2 Lung Neoplasms 2 Kidney Neoplasms 2 HER2-positive Breast Cancer 2 Esophageal Neoplasms 2 Vulvar Neoplasms 1 Urologic Neoplasms 1

Interventions

Paclitaxel 3 Doxorubicin 3 Cyclophosphamide 3 Trastuzumab 2 Surgical Procedures, Operative 2 Carboplatin 2 pertuzumab 1 liposomal doxorubicin 1 cemiplimab 1 atezolizumab 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Lapatinib 1 Indocyanine Green 1 Anastrozole 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Invasive Breast Cancer × atezolizumab × Breast × Clear all

NCT03595592 2024-03-06

APTneo

Fondazione Michelangelo

Phase 3 Active not recruiting

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡